flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the European Medicines Agency (EMA) has accepted Gedeon Richter’s (hereinafter: “Richter”) regulatory submission for Estelle®, a combined oral contraceptive containing estetrol (E4) and drospirenone.

Patients | 27 February 20
Read more
27
Feb
2020

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the European Medicines Agency (EMA) has accepted Gedeon Richter’s (hereinafter: “Richter”) regulatory submission for Estelle®, a combined oral contraceptive containing estetrol (E4) and drospirenone.

26
Feb
2020

MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below

26
Feb
2020

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

25
Feb
2020

European Union and Flemish government support FOx Biosystems with €884 000

FOx Biosystems, a spin-off company from the KU Leuven, uses an innovative biosensor technology that allows both kinetic characterization and quantifications directly in the sample within the life sciences sector. Users are able to generate high quality biomolecular data in a fast, straightforward and cost-effective way ideally suited for industry 4.0. The aim is therefore to revolutionize the life science industry and research market with this modern technique.

25
Feb
2020

argenx to Present at Cowen 40th Annual Health Care Conference

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 12:00 p.m. ET in Boston.

27
Feb
2020

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the European Medicines Agency (EMA) has accepted Gedeon Richter’s (hereinafter: “Richter”) regulatory submission for Estelle®, a combined oral contraceptive containing estetrol (E4) and drospirenone.

26
Feb
2020

MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below

26
Feb
2020

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

25
Feb
2020

European Union and Flemish government support FOx Biosystems with €884 000

FOx Biosystems, a spin-off company from the KU Leuven, uses an innovative biosensor technology that allows both kinetic characterization and quantifications directly in the sample within the life sciences sector. Users are able to generate high quality biomolecular data in a fast, straightforward and cost-effective way ideally suited for industry 4.0. The aim is therefore to revolutionize the life science industry and research market with this modern technique.

25
Feb
2020

argenx to Present at Cowen 40th Annual Health Care Conference

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 12:00 p.m. ET in Boston.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?